Nitrase Therapeutics is developing drugs against newly discovered nitration enzyme(s).
Nitrase Therapeutics has raised $7.0M in total funding. The most recent round was Series A. The last funding was announced in November 2021.
Nitrase Therapeutics's investors include Sofinnova Partners, Michael J. Fox Foundation, AbbVie, Dementia Discovery Fund, Bristol-Myers Squibb.
Nitrase Therapeutics is headquartered in Jackson, United States.
Nitrase Therapeutics is developing drugs against newly discovered nitration enzyme(s).
Nitrase Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Nitrase Therapeutics — Funding & Investors." VCBacked, November 2, 2021, https://www.vcbacked.co/company/nitrase-therapeutics. Accessed September 29, 2026.
VCBacked. (2021). Nitrase Therapeutics — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/nitrase-therapeutics
{{cite web |title=Nitrase Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/nitrase-therapeutics |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated